Dr. Martens (DOCS) Share Price, News & Analysis

Company Overview

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over 60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the 1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and accessories. The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and is a constituent of the FTSE 250 index. Dr. Martens operates across three geographic regions: EMEA, Americas and APAC. Our product segments include Originals, Fusion, Kids and Casual and a complementary range of Accessories.

Key Stats

• Today's Range: 68.20 to 72.10
• 50-Day Range: 60.70 to 74
• 52-Week Range: 59 to 100.87
• Volume: 1.32 million shs
• Average Volume: 9.13 million shs
• Market Capitalization: £687.67 million
• P/E Ratio: 29.63
• Dividend Yield: 3.50%
• Price Target: GBX 105
• Consensus Rating: Moderate Buy

Dr. Martens Stock Analysis - MarketRank™

Dr. Martens scored higher than 83% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Dr. Martens has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

Dr. Martens has a consensus price target of GBX 105, representing about 48.9% upside from its current price of GBX 70.50.

Amount of Analyst Coverage

Dr. Martens has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Dr. Martens is 29.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of Dr. Martens is 29.38, which means that it is trading at a less expensive P/E ratio than the Consumer Cyclical sector average P/E ratio of about 76.54.

Price to Earnings Growth Ratio

Dr. Martens has a PEG Ratio of 6.40. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Dr. Martens has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for DOCS.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Leadership

Dr. Martens is a leading dividend payer. It pays a dividend yield of 3.50%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Dr. Martens does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Dr. Martens is 106.25%. Payout ratios above 75% are not desirable because they may not be sustainable.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.71

News Sentiment

Dr. Martens has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Consumer Cyclical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Dr. Martens this week, compared to 2 articles on an average week.

Search Interest

26 people have searched for DOCS on MarketBeat in the last 30 days. This is an increase of 24% compared to the previous 30 days.

Company Ownership

• Score: 2.6 / 5
• Insider Trading: Selling Shares

Cluster Insider Buying

2 insiders have purchased shares of Dr. Martens in the last three months. Multiple insiders buying is a strong bullish signal.

Insider Buying vs. Insider Selling

In the past three months, Dr. Martens insiders have sold 22,351.60% more of their company's stock than they have bought. Specifically, they have bought £599.84 in company stock and sold £134,673.66 in company stock.

Percentage Held by Insiders

2.81% of the stock of Dr. Martens is held by insiders.

Percentage Held by Institutions

32.17% of the stock of Dr. Martens is held by institutions.

Company Calendar

• Last Earnings: 5/19/2026
• Today: 6/04/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Consumer Cyclical
• Industry: Footwear & Accessories
• Sub-Industry: Computer Software
• Current Symbol: LON:DOCS
• CIK: N/A
• Web: www.drmartensplc.com
• Phone: 44 12 1415 7047
• Fax: N/A
• Employees: 890
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Dr. Martens: GBX 105
• High Price Target: GBX 110
• Low Price Target: GBX 100
• Potential Upside/Downside: +47.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 2.40
• Trailing P/E Ratio: 29.63
• Forward P/E Ratio: 27.55
• P/E Growth: 6.4
• Net Income: £68.97 million
• Net Margins: 3.11%
• Pretax Margin: N/A
• Return on Equity: 6.89%
• Return on Assets: 8.12%

Debt

• Debt-to-Equity Ratio: 108.27
• Current Ratio: 2.61
• Quick Ratio: 1.13

Sales & Book Value

• Annual Sales: £764.90 million
• Price / Sales: 0.90
• Cash Flow: GBX 4.98 per share
• Price / Cash Flow: 14.29
• Book Value: GBX 37.80 per share
• Price / Book: 1.88

Miscellaneous

• Outstanding Shares: 967,193,000
• Free Float: N/A
• Market Cap: £687.67 million
• Optionable: Not Optionable
• Beta: 0.22